Yestar Health (02393) has released its interim results for the six months ended June 30, 2026, revealing a net loss attributable to shareholders of RMB 3.168 million, a sharp reversal from the profit of RMB 5.761 million recorded during the same period last year.

The company generated revenue of RMB 662 million for the period, marking a 17.57% decline year-on-year. The loss per share stood at RMB 0.14 cent.

According to the announcement, the drop in revenue is primarily attributed to the medical segment—the group's main income source—which has been adversely impacted by China's centralized procurement policies.